Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Teicher

Showing results (11-20 of 244) with videos related to

Pageof 25
Sort By:
Current Cancer Drug Targets|December 23, 2009
Antibody-drug conjugate targetsB A Teicher
Current Pharmaceutical Design|July 27, 2001
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptidesC Shih, B A Teicher
Investigational New Drugs|January 1, 1997
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agentsY Kakeji, B A Teicher
Cancer Chemotherapy and Pharmacology|January 1, 1988
Development of alkylating agent-resistant human tumor cell linesB A Teicher, E Frei
Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 1, 1996
Cyclooxygenase and lipoxygenase inhibitors in cancer therapyG Ara, B A Teicher
Cancer Treatment and Research|January 1, 1991
Modulation of antitumor alkylating agents (AA)B A Teicher, E Frei
Science (New York, N.Y.)|March 2, 1984
Perfluorochemical emulsions can increase tumor radiosensitivityB A Teicher, C M Rose
Radiation Research|January 1, 1987
Antitumor and radiosensitizing activity of several platinum-(+) dye complexesB A Teicher, S A Holden
International Journal of Radiation Oncology, Biology, Physics|August 1, 1986
Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DAB A Teicher, C M Rose
Cancer Research|May 15, 1988
Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcomaT S Herman, B A Teicher
Pageof 25

Showing results (11-20 of 244) with videos related to

Sort By:
Pageof 25
Current Cancer Drug Targets|December 23, 2009
Antibody-drug conjugate targetsB A Teicher
Current Pharmaceutical Design|July 27, 2001
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptidesC Shih, B A Teicher
Investigational New Drugs|January 1, 1997
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agentsY Kakeji, B A Teicher
Cancer Chemotherapy and Pharmacology|January 1, 1988
Development of alkylating agent-resistant human tumor cell linesB A Teicher, E Frei
Prostaglandins, Leukotrienes, and Essential Fatty Acids|January 1, 1996
Cyclooxygenase and lipoxygenase inhibitors in cancer therapyG Ara, B A Teicher
Cancer Treatment and Research|January 1, 1991
Modulation of antitumor alkylating agents (AA)B A Teicher, E Frei
Science (New York, N.Y.)|March 2, 1984
Perfluorochemical emulsions can increase tumor radiosensitivityB A Teicher, C M Rose
Radiation Research|January 1, 1987
Antitumor and radiosensitizing activity of several platinum-(+) dye complexesB A Teicher, S A Holden
International Journal of Radiation Oncology, Biology, Physics|August 1, 1986
Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DAB A Teicher, C M Rose
Cancer Research|May 15, 1988
Sequencing of trimodality therapy [cis-diamminedichloroplatinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcomaT S Herman, B A Teicher
Pageof 25